Citations

Clear

16281 citation(s) found for "Yu, David".

S801 Dose-Related Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function
Lupianez‐Merly, Camille , Busciglio, Irene, Eckert, Deborah J., Ryks, Michael, Dyer, Roy B. , Vizenor, Brady A., Zhao, Yuxi , Sapone, Anna, Rooks, Michelle, Gale, Jeremy D. , Camilleri, Michael , Yang, David Yi , Jencks, Kara J. , Dilmaghani, Saam , Vizenor, Brady A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S552-S553

10.14309/01.ajg.0001032572.47643.cf Get It

S758 Resilience in Patients With Functional Dyspepsia: A Prospective Questionnaire Study
Chase, Robert C., Cangemi, David J. , Keefer, Laurie , Chase, Katherine Johnson, Lacy, Brian E. , Chase, Robert C., Lacy, Brian E.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S520-S520

10.14309/01.ajg.0001032400.92789.6d Get It

CNS manifestations in acute and chronic graft-versus-host disease
Lambert, Nicolas , Forte, Florence, Monseur, Justine, Raus, Nicole, Shultz, Carl , Balaguer‐Roselló, Aitana , Gil‐Perotín, Sara , Brijs, Jan , Chauvet, Paul , Carré, Martin , Dulămea, Adriana Octaviana , Salmenniemi, Urpu , Nguyen, Stéphanie , Smallbone, Portia , González‐Vicent, Marta , Willems, Évelyne, Baron, Frédéric , Servais, Sophie , Béguin, Yves , Maquet, Pierre , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Dulamea, Adriana Octaviana, Tănase, Alina , Salmenniemi, Urpu, Butera, Sara , Piekarska, Agnieszka , Davies, J. M., Labussière-Wallet, Hélène, D’Aveni, Maud , Willems, Evelyne, Gil-Perotín, Sara , Chalandon, Yves , Santoro, Jonathan D , Servais, Sophie , Lambert, Nicolas , Moussaoui, Majdouline El , Raus, Nicole, Polushin, Alexey Yu. , Michonneau, David , Hogan, William J. , Gavriilaki, Maria , Chalandon, Yves , Duminuco, Andrea , Ram, Ron , García‐Cadenas, Irene , Porto, Gaetana , Santoro, Jonathan D. , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Skiba, Iaroslav B. , Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Sakellari, Ioanna , Dulamea, Adriana Octaviana, Chantepie, Sylvain , Salmenniemi, Urpu, Loschi, Michael L. , Martino, Massimo , Mensah‐Glanowska, Patrycja , Labussière-Wallet, Hélène, Hamadani, Mehdi , Willems, Evelyne

Mayo Clinic

Brain | October 23, 2024 | Volume: 148 | Issue: 4 | Pages: 1122-1133

10.1093/brain/awae340 | PMID 39442000 Get It

Abstract Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective study, we analysed the clinical, biological, radiological and histopathological characteristics, as well as the clinical course of 66 patients diagnosed with possible CNS-GvHD (pCNS-GvHD), selected by predetermined diagnostic criteria. Results were then contrasted depending on whether pCNS-GvHD onset occurred before or after Day 100 following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The median time between allo-HSCT and pCNS-GvHD onset was 149 days (interquartile range25–75 48–321), and pCNS-GvHD onset occurred before Day 100 following transplantation in 44% of patients. The most frequent findings at presentation were cognitive impairment (41%), paresis (21%), altered consciousness (20%), sensory impairment (18%) and headache (15%). Clinical presentation did not significantly differ between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Brain MRI found abnormalities compatible with the clinical picture in 57% of patients, while CT detected abnormalities in only 7%. Seven patients had documented spinal cord MRI abnormalities, all of them with pCNS-GvHD occurring after Day 100 following transplantation. In the CSF, the white blood cell count was increased in 56% of the population (median 18 cells/μl). Histopathological analyses were performed on 12 specimens and were suggestive of pCNS-GvHD in 10. All compatible specimens showed parenchymal and perivascular infiltration by CD3+ and CD163+ cells. Immunosuppressive therapy was prescribed in 97% of patients, achieving complete clinical response in 27%, partial improvement in 47% and stable disease in 6%. Response to immunosuppressive therapy did not differ significantly between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Clinical relapse was observed in 31% of patients who initially responded to treatment. One-year overall survival following pCNS-GvHD onset was 41%. Onset before Day 100 following haematopoietic stem cell transplantation [hazard ratio with 95% confidence interval: 2.1 (1.0–4.5); P = 0.041] and altered consciousness at initial presentation [3.0 (1.3–6.7); P = 0.0077] were associated with a reduced 1-year overall survival probability. Among surviving patients, 61% had neurological sequelae. This study supports that immune-mediated CNS manifestations may occur following allo-HSCT. These can be associated with both acute and chronic GvHD and carry a grim prognosis. The clinical presentation as well as the radiological and biological findings appear variable.
Recommendations for permanent sleep telehealth: an American Academy of Sleep Medicine position statement
Vohra, Kunwar Praveen, Johnson, Karin G. , Dalal, A, Ibrahim, Sally , Krishnan, Vidya , Abbasi-Feinberg, Fariha, Abreu, Alexandre Rocha, Bandyopadhyay, Anuja , Gurubhagavatula, Indira , Kuhlmann, David, Olson, Eric J. , Shelgikar, Anita V., Trotti, Lynn Marie , Rowley, James A. , Trotti, Lynn Marie , Martin, Jennifer L. , Patil, Susheel P. , Wickwire, Emerson M. , Kapur, Vishesh K.

Mayo Clinic

Journal of Clinical Sleep Medicine | October 23, 2024 | Volume: 21 | Issue: 2 | Pages: 401-404

10.5664/jcsm.11438 | PMID 39441539 Get It

Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center
McHugh, Jack , Bayless, David R., Ranganath, Nischal , Kind, Dalton R., Wengenack, Nancy L. , Shah, Aditya , McHugh, Jack , Wengenack, Nancy L , Shah, Aditya S , Ranganath, Nischal , Bayless, David R., Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | October 23, 2024 | Volume: 62 | Issue: 11 | Pages: No page available

10.1128/jcm.01057-24 | PMID 39440933 Get It

ABSTRACT The prevalence of invasive candidiasis caused by non- albicans Candida species is increasing. Candida guilliermondii is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with C. guilliermondii are sparse. Our study evaluated the antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference laboratory over a 12-year period (2012–2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with C. guilliermondii fungemia. One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8–20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles. IMPORTANCE Our study addresses a significant knowledge gap in the clinical management of this non- Candida albicans species. Our retrospective review includes comprehensive AST data for 112 Candida guilliermondii isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.
Community-Engaged Approaches for Improving the Inclusion of Diverse Communities in a Nutrition Clinical Trial
Adeyemo, Mopelola A. , Trinh, Jessica , Perez, Darian, Bozeman, Estabon, Ntekume, Ejiro , Gardner, Jachael, Thames, Gail, Vassar, Stefanie D. , Li, Zhaoping , Brown, Arleen F. , Li, Zhaoping , Luong, Tiffany Q. , Carson, Savanna L. , Norris, Keith C. , Casillas, Alejandra

Mayo Clinic

Nutrients | October 23, 2024 | Volume: 16 | Issue: 21 | Pages: 3592

10.3390/nu16213592 | PMID 39519425 Get It

Background: Cardiometabolic disease (CMD) disproportionately affects African American/Black (AA) and Latino communities. CMD disparities are exacerbated by their underrepresentation in clinical trials for CMD treatments including nutritional interventions. The study aimed to (1) form a precision nutrition community consultant panel (PNCCP) representative of Latino and AA communities in Los Angeles to identify barriers and facilitators to recruitment and retention of diverse communities into nutrition clinical trials and (2) develop culturally informed strategies to improve trial diversity. Methods: A deliberative community engagement approach was used to form a PNCCP for the Nutrition for Precision Health (NPH) trial, part of the of the All of Us research initiative. The PNCCP included individuals that provide services for Latino and AA communities who met during 11 virtual sessions over 1 year. Discussion topics included enhancing recruitment and cultural acceptance of the NPH trial. We summarized CCP recommendations by theme using an inductive qualitative approach. Results: The PNCCP included 17 adults (35% AA, 47% Latino). Four thematic recommendations emerged: reducing structural barriers to recruitment, the need for recruitment materials to be culturally tailored and participant-centered, community-engaged trial recruitment, and making nutrition trial procedures inclusive and acceptable. We outlined the study response to feedback, including the constraints that limited implementation of suggestions. Conclusion: This study centers community voices regarding the recruitment and retention of AA and Latino communities into a nutrition clinical trial. It highlights the importance of community engagement early on in protocol development and maintaining flexibility to enhance inclusion of diverse communities in nutrition clinical trials.
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
Visram, Alissa , Larson, Dirk R. , Murray, David , Kyle, Robert A. , Slager, Susan L. , Kumar, Shaji , Vachon, Celine M. , Larson, Dirk , Norman, Aaron, Dispenzieri, Angela , Slager, Susan L , Kumar, Shaji K , Vachon, Celine M. , Visram, Alissa , Norman, Aaron D. , Dispenzieri, Angela , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 22, 2024 | Volume: 145 | Issue: 3 | Pages: 325-333

10.1182/blood.2024025415 | PMID 39437710 Get It

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant disorder. The current standard of care is not to screen for MGUS, so it is often incidentally diagnosed in the clinic. It is unknown whether the outcomes of screened vs clinically detected MGUS differ. We compared the progression risk between screened vs clinical MGUS cohorts and assessed whether the MGUS detection method affected risk prediction of established clinical factors (score). We included 379 screened MGUS cases from the Olmsted County population-based study and 1384 patients with MGUS diagnosed during routine clinical evaluation at Mayo Clinic. Median follow-up time for the screened vs clinical cohort was 26.6 and 40.1 years, respectively. Accounting for death as a competing risk, the cumulative incidence of progression at 25 years was similar in the screened (11.1% [95% confidence interval [CI], 8.3-14.8]) vs clinical (10.1% [95% CI, 8.6-11.8]) MGUS cohorts, even when stratified by sex, age, or the baseline MGUS risk score. Overall, 0.9 (95% CI, 0.6-1.2) of patients with screened MGUS vs 1.0 (95% CI, 0.9-1.2) of those with clinically detected MGUS experienced disease progression for every 100 person-years of follow-up. MGUS detection method did not modify the association between MGUS risk score and progression risk (pinteraction = 0.217) and did not add to known risk factors for progression (likelihood ratio test; P = .839). Here, we show that progression risk among patients with screened vs clinically detected heavy-chain MGUS was similar. Future studies are needed to assess whether tailored follow-up of patients with screened MGUS affects clinical outcomes.
Comparative analysis of single plane and biplane angiography systems for mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis
Orscelik, Atakan , Bilgin, Cem , Cortese, Jonathan , Cayme, Joshua J , Şenol, Yiğit Can , Musmar, Basel , Ghozy, Sherief , Bayraktar, Esref Alperen , Beizavi, Zahra , Brinjikji, Waleed , Kallmes, David F. , Senol, Yigit Can , Musmar, Basel , Ghozy, Sherief , Bayraktar, Esref Alperen , Brinjikji, Waleed , Orscelik, Atakan , Cortese, Jonathan , Zandpazandi, Sara

Mayo Clinic

Journal of NeuroInterventional Surgery | October 22, 2024 | Volume: 17 | Issue: 6 | Pages: 567-573

10.1136/jnis-2024-022381 | PMID 39438134 Get It

Background The choice of angiography system could influence the outcomes of mechanical thrombectomy (MT) in the treatment of acute ischemic stroke (AIS), but its impact is not yet well understood. This study aims to compare the clinical and technical outcomes of MT performed with single plane versus biplane angiography systems. Method We conducted a systematic review and meta-analysis, following PRISMA guidelines, by searching PubMed, Embase, Web of Science, and Scopus to include studies on patients with AIS who underwent MT with either single plane or biplane angiography up to May 4, 2024. The primary outcome was a favorable outcome defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after the procedure. Data were analyzed using a random-effects model and heterogeneity was assessed using the I2 test and Q statistics. Results Five studies with a total of 1562 patients were analyzed. Of these, 68.4% were treated with biplane systems and 31.6% with single plane systems. Single plane angiography was associated with a significantly higher rate of favorable outcomes (OR 1.43; 95% CI 1.13 to 1.80; P<0.01). There were no significant differences in successful recanalization, periprocedural complications, procedure time, total fluoroscopy time, or contrast volume between the two systems. Conclusion While single plane angiography systems may offer slightly better outcomes in MT for AIS, both systems appear equally effective in most clinical and technical perspectives, suggesting that system selection may be more dependent on availability and procedural requirements rather than inherent superiority. Our findings may encourage clinicians to use single-plane angiography in settings where the biplane angiography suite availability is limited, but it should be noted that this observation may have been influenced by selection bias, particularly since the larger studies included in our meta-analysis did not observe this effect in adjusted analyses for potential confounder factors.
Endovascular therapy versus medical management in isolated posterior cerebral artery acute ischemic stroke: A multinational multicenter propensity score-weighted study
Salim, Hamza , Pulli, Benjamin , Yedavalli, Vivek, Musmar, Basel , Adeeb, Nimer , Lakhani, Dhairya A. , Essibayi, Muhammed Amir , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil G. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Faizy, Tobias D , Wintermark, Max , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Pulli, Benjamin , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil, Puri, Ajit S , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | October 21, 2024 | Volume: 10 | Issue: 2 | Pages: 387-396

10.1177/23969873241291465 | PMID 39431327 Get It

Abstract Background: Despite the proven effectiveness of endovascular therapy (EVT) in acute ischemic strokes (AIS) involving anterior circulation large vessel occlusions, isolated posterior cerebral artery (PCA) occlusions (iPCAo) remain underexplored in clinical trials. This study investigates the comparative effectiveness and safety of EVT against medical management (MM) in patients with iPCAo. Methods: This multinational, multicenter propensity score-weighted study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. We included iPCAo patients treated with either EVT or MM. The primary outcome was the modified Rankin Scale (mRS) at 90 days, with secondary outcomes including functional independence, mortality, and safety profiles such as hemorrhagic complications. Results: A total of 177 patients were analyzed (88 MM and 89 EVT). EVT showed a statistically significant improvement in 90-day mRS scores (OR = 0.55, 95% CI = 0.30–1.00, p = 0.048), functional independence (OR = 2.52, 95% CI = 1.02–6.20, p = 0.045), and a reduction in 90-day mortality (OR = 0.12, 95% CI = 0.03–0.54, p = 0.006) compared to MM. Hemorrhagic complications were not significantly different between the groups. Conclusion: EVT for iPCAo is associated with better neurological outcomes and lower mortality compared to MM, without an increased risk of hemorrhagic complications. Nevertheless, these results should be interpreted with caution due to the study’s observational design. The findings are hypothesis-generating and highlight the need for future randomized controlled trials to confirm these observations and establish definitive treatment guidelines for this patient population.